Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial
- 30 June 1998
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 69 (3), 226-229
- https://doi.org/10.1006/gyno.1998.5016
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Hexamethylmelamine/Altretamine as Second-Line Therapy for Epithelial Ovarian CarcinomaGynecologic Oncology, 1993
- Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancerGynecologic Oncology, 1992
- Hexamethylmelamine as a single second-line agent in ovarian cancerGynecologic Oncology, 1990
- Chemotherapy for advanced or recurrent gynecologic cancerCancer, 1987
- Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapyGynecologic Oncology, 1987
- Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinomaCancer, 1984
- Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapyGynecologic Oncology, 1984
- A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinomaCancer, 1983
- Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinomaJournal of Surgical Oncology, 1982
- cis-Platinum-hexamethylmelamine therapy of advanced ovarian cancerGynecologic Oncology, 1981